Organisation paid for research Program year 2021 Source: CMS Open Payments

Solutions Through Advanced Research Inc.

Neither a doctor nor a teaching hospital

Research payments

$202,464

43 payments

Through program year 2021, Solutions Through Advanced Research Inc. is reported as receiving $202,464 in research payments, across 43 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$7,438	1
2020	Research	$127,811	22
2019	Research	$67,215	20

Breakdown

Who paid Research payments · program years 2019–2021

Amgen Inc. $105,114 8 payments
Bayer HealthCare Pharmaceuticals Inc. $52,733 33 payments
Celgene Corporation $44,618 2 payments

Studies the money was for Research payments · program years 2019–2021

Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate to Severe Plaque PSO (PPSO-003) $91,288 2 payments
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years With Moderate to Severe Plaque Psoriasis (Cc-10004-Ppso-003) $44,618 2 payments
Bay1002670 Fibroids Efficacy US / EU $28,119 22 payments
BAY1002670 Long term Safety vs SoC $23,021 10 payments
Open Label Extension study for PPSO-003 (PPSO-004) $8,220 2 payments
Efficacy and Safety Study of Apremilast CC-10004 in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psor $4,213 2 payments
Bay1002670 Endometriosis Dose finding EU & US JP CN $1,593 1 payment
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psor $893 1 payment
A Long-term Extension Study of Apremilast CC-10004 in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Ps $499 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.